Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 21;11(3):496.
doi: 10.3390/vaccines11030496.

Dynamics of Anti-S IgG Antibodies Titers after the Second Dose of COVID-19 Vaccines in the Manual and Craft Worker Population of Qatar

Devendra Bansal  1 , Hassan Atia  1 , Mashael Al Badr  2 , Mohamed Nour  1 , Jazeel Abdulmajeed  3   4 , Amal Hasan  2 , Noora Al-Hajri  2 , Lina Ahmed  1 , Rumissa Ibrahim  1 , Reham Zamel  1 , Almuthana Mohamed  1 , Hamad Pattalaparambil  1 , Faisal Daraan  1 , Adil Chaudhry  1 , Sahar Oraby  1 , Sahar El-Saleh  1 , Sittana S El-Shafie  2 , Affra Faiz Al-Farsi  5 , Jiji Paul  5 , Ahmed Ismail  5 , Hamad Eid Al-Romaihi  1 , Mohammed Hamad Al-Thani  1 , Suhail A R Doi  4 , Susu M Zughaier  6 , Farhan Cyprian  6 , Elmobashar Farag  1 , Habib Hasan Farooqui  4
Affiliations

Dynamics of Anti-S IgG Antibodies Titers after the Second Dose of COVID-19 Vaccines in the Manual and Craft Worker Population of Qatar

Devendra Bansal et al. Vaccines (Basel). .

Abstract

There is limited seroepidemiological evidence on the magnitude and long-term durability of antibody titers of mRNA and non-mRNA vaccines in the Qatari population. This study was conducted to generate evidence on long-term anti-S IgG antibody titers and their dynamics in individuals who have completed a primary COVID-19 vaccination schedule. A total of 300 male participants who received any of the following vaccines BNT162b2/Comirnaty, mRNA-1273, ChAdOx1-S/Covishield, COVID-19 Vaccine Janssen/Johnson, or BBIBP-CorV or Covaxin were enrolled in our study. All sera samples were tested by chemiluminescent microparticle immunoassay (CMIA) for the quantitative determination of IgG antibodies to SARS-CoV-2, receptor-binding domain (RBD) of the S1 subunit of the spike protein of SARS-CoV-2. Antibodies against SARS-CoV-2 nucleocapsid (SARS-CoV-2 N-protein IgG) were also determined. Kaplan-Meier survival curves were used to compare the time from the last dose of the primary vaccination schedule to the time by which anti-S IgG antibody titers fell into the lowest quartile (range of values collected) for the mRNA and non-mRNA vaccines. Participants vaccinated with mRNA vaccines had higher median anti-S IgG antibody titers. Participants vaccinated with the mRNA-1273 vaccine had the highest median anti-S-antibody level of 13,720.9 AU/mL (IQR 6426.5 to 30,185.6 AU/mL) followed by BNT162b2 (median, 7570.9 AU/mL; IQR, 3757.9 to 16,577.4 AU/mL); while the median anti-S antibody titer for non-mRNA vaccinated participants was 3759.7 AU/mL (IQR, 2059.7-5693.5 AU/mL). The median time to reach the lowest quartile was 3.53 months (IQR, 2.2-4.5 months) and 7.63 months (IQR, 6.3-8.4 months) for the non-mRNA vaccine recipients and Pfizer vaccine recipients, respectively. However, more than 50% of the Moderna vaccine recipients did not reach the lowest quartile by the end of the follow-up period. This evidence on anti-S IgG antibody titers should be considered for informing decisions on the durability of the neutralizing activity and thus protection against infection after the full course of primary vaccination in individuals receiving different type (mRNA verus non-mRNA) vaccines and those with natural infection.

Keywords: COVID-19; anti-S IgG; antibody titer; mRNA vaccines; non-mRNA vaccines.

PubMed Disclaimer

Conflict of interest statement

We would like to declare that all serological test kits used in this study were provided as in-kind support for the laboratory section at Medical Commission, MOPH. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Figures

Figure 1
Figure 1
Anti-S IgG antibodies titers (AU/mL) stratified by Moderna and Pfizer vaccinees and history of prior SARS-CoV-2 infection (anti-NC IgG antibodies).
Figure 2
Figure 2
Kaplan–Meier cumulative survival comparing the probability of retaining anti-S IgG antibodies (seroprotection) among mRNA versus non-mRNA vaccinees.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. WHO WHO Coronavirus (COVID-19) Dashboard. 2022. [(accessed on 5 September 2022)]. Available online: https://covid19.who.int/?gclid=EAIaIQobChMIkazL-ojJ8gIVjpGyCh1iEgKXEAAYA....
    1. Zhu N., Zhang D., Wang W., Li X., Yang B., Song J., Zhao X., Huang B., Shi W., Lu R., et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 2020;382:727–733. doi: 10.1056/NEJMoa2001017. - DOI - PMC - PubMed
    1. MOPH Ministry of Public Health Qatar 2022. [(accessed on 5 September 2022)]; Available online: https://covid19.moph.gov.qa/EN/Pages/default.aspx.
    1. Flacco M.E., Acuti Martellucci C., Soldato G., Carota R., Fazii P., Caponetti A., Manzoli L. Rate of reinfections after SARS-CoV-2 primary infection in the population of an Italian province: A cohort study. J. Public Health. 2021;44:e475–e478. doi: 10.1093/pubmed/fdab346. - DOI - PMC - PubMed
    1. Hall V.J., Foulkes S., Charlett A., Atti A., Monk E.J.M., Simmons R., Wellington E., Cole M.J., Saei A., Oguti B., et al. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: A large, multicentre, prospective cohort study (SIREN) Lancet. 2021;397:1459–1469. doi: 10.1016/S0140-6736(21)00675-9. - DOI - PMC - PubMed

LinkOut - more resources